Clinical trial
Clinical and Radiological Outcomes in People With Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab
NCT06398158 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical and Radiological Outcomes in People With Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab
- Lead sponsor
- University of Texas Southwestern Medical Center
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- July 10, 2024
- Completion date
- October 31, 2029
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.